Which statement about Carmustine is true?

Which statement about Carmustine is true?

• A. It is used for hormone receptor-positive breast cancer.
• B. It is a platinum-based chemotherapy with no brain tumor applications.
• C. It is used for primary and metastatic brain tumors.
• D. It has no hematologic toxicity.

Answer: (C)

Carmustine is a nitrosourea alkylating agent that penetrates the blood-brain barrier, allowing it to reach tumor cells in the brain. This property makes it a useful option for brain tumors, including both primary brain tumors and brain metastases. Therefore, the true statement is that it is used for primary and metastatic brain tumors. It is not platinum-based, as platinum drugs like cisplatin or carboplatin are a different class. It does have hematologic toxicity, causing bone marrow suppression, so claiming it has no hematologic toxicity is incorrect. Carmustine can be given systemically or delivered locally via Gliadel wafers to provide high local concentrations after brain tumor surgery.

Carmustine is a nitrosourea alkylating agent that penetrates the blood-brain barrier, allowing it to reach tumor cells in the brain. This property makes it a useful option for brain tumors, including both primary brain tumors and brain metastases. Therefore, the true statement is that it is used for primary and metastatic brain tumors. It is not platinum-based, as platinum drugs like cisplatin or carboplatin are a different class. It does have hematologic toxicity, causing bone marrow suppression, so claiming it has no hematologic toxicity is incorrect. Carmustine can be given systemically or delivered locally via Gliadel wafers to provide high local concentrations after brain tumor surgery.